Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Follicular Lymphoma With EZH2”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)Study completedNCT05467943
What this trial is testing

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Who this might be right for
Relapsed/Refractory Follicular Lymphoma With EZH2
Hutchmed 42
Testing effectiveness (Phase 2)WithdrawnNCT06068881
What this trial is testing

Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

Who this might be right for
Follicular LymphomaRefractory Follicular Lymphoma
Epizyme, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT04224493
What this trial is testing

Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Who this might be right for
Relapsed/Refractory Follicular LymphomaFollicular LymphomaRefractory Follicular Lymphoma
Epizyme, Inc. 599
Early research (Phase 1)Looking for participantsNCT03460977
What this trial is testing

Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)
Pfizer 453
Testing effectiveness (Phase 2)Looking for participantsNCT07545603
What this trial is testing

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

Who this might be right for
Follicular Lymphoma, Grade 1Follicular Lymphoma, Grade 2Follicular Lymphoma, Grade 3+1 more
Evopoint Biosciences Inc. 65
Not applicableActive Not RecruitingNCT05228158
What this trial is testing

Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Who this might be right for
Lymphoma, Follicular
Eisai Co., Ltd. 145
Testing effectiveness (Phase 2)Study completedNCT03456726
What this trial is testing

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Co., Ltd. 20